Kailera Therapeutics, Inc.
SEC CIK 2096997 · KLRA · last insider filing 2026-06-11
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Renaud Ronald C JR | Director · CEO & President | filed 2026 - 2026 |
| Milligan John F | Director | filed 2026 - 2026 |
| Mackay Martin | Director | filed 2026 - 2026 |
| Koppel Adam | Director | filed 2026 - 2026 |
| Kaplan Andrew T. | Director | filed 2026 - 2026 |
| Clyburn Frank | Director | filed 2026 - 2026 |
| Hite Christopher | Director | filed 2026 - 2026 |
| Liu Yuting | Director | filed 2026 - 2026 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Pagan Douglas W. | Chief Financial Officer | filed 2026 - 2026 |
| Burgess Paul D. | See Remarks | filed 2026 - 2026 |
| Cloghessy Paula | Chief People Officer | filed 2026 - 2026 |
| Akamine Scott | Chief Legal Officer | filed 2026 - 2026 |
| Coleman Jamie Beth | Chief Commercial Officer | filed 2026 - 2026 |
| Wasserman Scott M. | Chief Medical Officer | filed 2026 - 2026 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.